Brazil · Delayed Price · Currency is BRL Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcripts
Fiscal Year 2025
-
Sales grew 17% in 2025, with digital and own-brand products driving revenue and margin gains. GLP-1 drugs now represent 11% of sales, with generics expected to boost growth and margins in 2026. Strong cash flow, improved leverage, and a clear path to double revenue by 2030.
-
Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.
-
Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.
-
Q1 2025 saw 15.9% sales growth, stable 29.4% retail gross margin, and 7% EBITDA growth, driven by mature store productivity, digital expansion, and private label gains. Market share increased for the 20th consecutive quarter, with strong cash flow and low leverage.
Fiscal Year 2024
-
Q4 2024 saw nearly 18% sales growth and record EBITDA, despite flood disruptions earlier in the year. The company exited wholesale, expanded its retail and digital footprint, and expects continued margin expansion and strong sales in 2025, supported by new product launches and maturing stores.
-
Q3 2024 saw 17% revenue growth, margin expansion, and strong digital sales, rebounding from Q2's flood impact. Market share increased across all southern states, with robust store expansion and disciplined leverage management. Guidance for 2024 and 2025 remains positive.
-
Q2 2024 saw 11.5% sales growth despite severe flooding, with rapid operational recovery and robust digital and service segment performance. Adjusted EBITDA was BRL 49 million, and leverage dropped to 0.84x. Guidance for 15–17% H2 growth and 60 new stores remains intact.